Howard Glass, DO
Cardiovascular Disease · Westbrook, MENPI 1063443539
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,325 of the $12,924 with a category attached, or 79.9%. Boehringer Ingelheim accounts for 62.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $12,371 and has fallen 99.5% since, to $58 in 2025. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $243.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- E.r. Squibb & Sons, L.L.C.$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$166
- Boston Scientific$144
- Shockwave Medical, Inc$134
- AstraZeneca$73
- plus $219 from 8 others
Across 1 payment — averaging $234.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$235
What the payments were for
- Speaking & faculty fees$10,32580%
- Travel & lodging$1,31110%
- Food & beverage$1,28710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 15 | $8,120 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,068 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $166 |
| Boston Scientific | 1 | $144 |
| Shockwave Medical, Inc | 3 | $134 |
| AstraZeneca | 4 | $73 |
| Johnson & Johnson | 3 | $70 |
| Novartis | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Amgen | 2 | $25 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,924 in reported general payments places this provider in the 95th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 689 | $802,621 |
| EntrestoSacubitril/Valsartan | 151 | $186,592 |
| JardianceEmpagliflozin | 104 | $110,348 |
| XareltoRivaroxaban | 83 | $108,501 |
| Repatha SureclickEvolocumab | 23 | $28,045 |
| FarxigaDapagliflozin Propanediol | 26 | $22,226 |
| Flecainide Acetate | 257 | $12,379 |
| Metoprolol Succinate | 628 | $10,863 |
| Atorvastatin Calcium | 402 | $4,897 |
| Amiodarone Hcl | 105 | $4,219 |
| Ranolazine ErRanolazine | 59 | $3,767 |
| Potassium Chloride | 85 | $3,035 |
| Carvedilol | 235 | $2,586 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 75 | $2,553 |
| Prasugrel Hcl | 45 | $2,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $38 | $186,592151 claims |
| Boehringer IngelheimJardiance | $8,120 | $110,348104 claims |
| Johnson & JohnsonXarelto | $70 | $108,50183 claims |
| AstraZenecaFarxiga | $73 | $22,22626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 cardiovascular disease providers in Maine.
Other cardiovascular disease in Westbrook
- John SmithWestbrook$325
- Ronald RosenfeldPerry$51K
- Jonathan HalevyAugusta$22K
- Jeffrey ColnesYork$22K
- Jaidip ChakravarttiScarborough$8K
- Adam KarpmanPortland$7K
- Marco DiazScarborough$6K
- Bram GellerPortland$5K
- Gemini YesodharanLewiston$4K
- Shiva AnnamalaiScarborough$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.